Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
McKinsey
Colorcon
AstraZeneca
Harvard Business School

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Huperzine A

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Huperzine A: Patents, clinical trial progress, indications

Huperzine A is an investigational drug.

There have been 11 clinical trials for Huperzine A. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2009.

The most common disease conditions in clinical trials are Alzheimer Disease, Cognition Disorders, and Dementia. The leading clinical trial sponsors are Biscayne Neurotherapeutics, Inc., Zhijun Bao, and Neuro-Hitech.

There are three hundred and seventy-nine US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Huperzine A
TitleSponsorPhase
BIS-001-ER for the Treatment of Adult Focal Impaired Awareness SeizuresBiscayne Neurotherapeutics Australia Pty, Ltd.Phase 1/Phase 2
BIS-001-ER for the Treatment of Adult Focal Impaired Awareness SeizuresBiscayne Neurotherapeutics, Inc.Phase 1/Phase 2
Bioavailability, Safety, and Tolerability of BIS-001 ERMelbourne HealthPhase 1

See all Huperzine A clinical trials

Clinical Trial Summary for Huperzine A

Top disease conditions for Huperzine A
Top clinical trial sponsors for Huperzine A

See all Huperzine A clinical trials

US Patents for Huperzine A

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Huperzine A   Start Trial Heterocyclic flavone derivatives, compositions, and methods related thereto Emory University (Atlanta, GA)   Start Trial
Huperzine A   Start Trial Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery Corium International, Inc. (Menlo Park, CA)   Start Trial
Huperzine A   Start Trial Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder Axovant Sciences GmbH (Basel, CH)   Start Trial
Huperzine A   Start Trial 2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,- 3-thiazol-4-yl amides Pfizer Inc. (New York, NY)   Start Trial
Huperzine A   Start Trial Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications AKER BIOMARINE ANTARCTIC AS (Stamsund, NO)   Start Trial
Huperzine A   Start Trial Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease Axovant Sciences GmbH (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Huperzine A

Drugname Country Document Number Estimated Expiration Related US Patent
Huperzine A China 104487429 2032-07-27   Start Trial
Huperzine A European Patent Office 2877461 2032-07-27   Start Trial
Huperzine A World Intellectual Property Organization (WIPO) 2014018741 2032-07-27   Start Trial
Huperzine A Australia 2017301928 2036-07-27   Start Trial
Huperzine A Australia 2017301929 2036-07-27   Start Trial
Huperzine A Australia 2017302305 2036-07-27   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Moodys
Medtronic
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.